Journals / Turkish Neurosurgery / 2019 / Cilt: 29 - Sayı: 6

The Effects of Agomelatine on The Biochemical and Pathological Features of Cisplatin-Induced Peripheral Neuropathy: The First Experimental Study in Rats

Pages
901–908
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

To our knowledge, this was the first study that showedthe positive effects of agomelatine on cisplatin-induced neuropathy in rats.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AIM: To evaluate the effects of agomelatine on the biochemical and pathological features of cisplatin-induced peripheral neuropathy.MATERIAL and METHODS: This study included a total of 30 male Wistar albino rats that weighed 285–300 grams and were dividedinto three groups: healthy controls (HC, n=10); cisplatin group (CIS, n=10) and agomelatine plus cisplatin group (AC, n=10).
📊
Key Findings & Data:The CISgroup received only cisplatin (EbeweLiba, Turkey) at a dose of 2.5 mg/kg, whereas the AC group received both agomelatine (25mg/kg, Les Laboratoires Servier, France) and cisplatin (2.5 mg/kg).
💡
Conclusion & Impact:To our knowledge, this was the first study that showedthe positive effects of agomelatine on cisplatin-induced neuropathy in rats.
🔬Design:Modeling & Simulation
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

AIM: To evaluate the effects of agomelatine on the biochemical and pathological features of cisplatin-induced peripheral neuropathy.MATERIAL and METHODS: This study included a total of 30 male Wistar albino rats that weighed 285–300 grams and were dividedinto three groups: healthy controls (HC, n=10); cisplatin group (CIS, n=10) and agomelatine plus cisplatin group (AC, n=10). The CISgroup received only cisplatin (EbeweLiba, Turkey) at a dose of 2.5 mg/kg, whereas the AC group received both agomelatine (25mg/kg, Les Laboratoires Servier, France) and cisplatin (2.5 mg/kg). The animals were sacrificed by thiopental anaesthesia (50 mg/kg, IE Ulagay, Turkey) and sciatic nerves were dissected. The sciatic nerve tissue was analysed for the levels of malondialdehyde(MDA), myeloperoxidase (MPO), total glutathione (tGSH) and superoxide dismutase (SOD) and was examined histopathologically.RESULTS: The mean levels of MDA, MPO, tGSH and SOD were 34.90 ± 13.83, 41.30 ± 18.03, 15.40 ± 6.06 and 48.60 ± 18.19,respectively. MDA and MPO were significantly lower in the AC group than in the CIS group (p<0.001 for both). However, the antioxidative parameters tGSH and SOD were significantly higher in the AC group than in the CIS group (p<0.001 for both). Pathologicalexaminations revealed swollen myelinated nerve fibres and evident myelin sheath degeneration in the CIS group; in the AC group,the myelin sheath degeneration was less and the blood vessels were normal.CONCLUSION: Agomelatine decreased the oxidative status in an experimental rat model of cisplatin-induced peripheral neuropathy.Myelin sheath degeneration was less in the AC group than in the CIS group. To our knowledge, this was the first study that showedthe positive effects of agomelatine on cisplatin-induced neuropathy in rats.

🔖

Cite This Article

YUCETAS, C. S., ÜÇLER, N., ÇAKIR, T. (2019). The Effects of Agomelatine on The Biochemical and Pathological Features of Cisplatin-Induced Peripheral Neuropathy: The First Experimental Study in Rats. Turkish Neurosurgery, Cilt: 29 - Sayı: 6, 901–908. https://ajindex.com/articles/404438

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Aguiar CC, Almeida AB, Araújo PV, Vasconcelos GS, Chaves EM, do Vale OC, Macêdo DS, Leal LK, de Barros Viana GS, Vasconcelos SM: Effects of Agomelatine on oxidative stress in the brain of mice after chemically induced seizures. Cell Mol Neurobiol 33:825-835, 2013 2. Albers JW, Chaudhry V, Cavaletti G, Donehower RC: Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 31: CD005228, 2014 3. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G: Chemotherapyinduced peripheral neurotoxicity (CIPN): An update. Crit Rev Oncol Hematol 82:51-77, 2012 4. Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, Iconomou G, Kalofonos HP: Vitamin E for prophylaxis against chemotherapy-induced neuropathy: A randomized controlled trial. Neurology 64:26-31, 2005 5. Argyriou AA, Chroni E, Polychronopoulos P, Iconomou G, Koutras A, Makatsoris T, Gerolymos MK, Gourzis P, Assimakopoulos K, Kalofonos HP: Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 67:2253-2255, 2006 6. Arrieta Ó, Hernández-Pedro N, Fernández-González-Aragón MC, Saavedra-Pérez D, Campos-Parra AD, Ríos-Trejo MÁ, Cerón-Lizárraga T, Martínez-Barrera L, Pineda B, Ordóñez G, Ortiz-Plata A, Granados-Soto V, Sotelo J: Retinoic acid reduces chemotherapy-induced neuropathy in an animal model and patients with lung cancer. Neurology 77:987-995, 2011 7. Aydin TH, Can OD, Demir OU, Turan N: Effect of subacute agomelatine treatment on painful diabetic neuropathy: Involvement of catecholaminergic mechanisms. Fundam Clin Pharmacol 30:549-567, 2016 8. Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, Zanna C, Gianni L: Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 41: 1746-1750, 2005 9. Bogliun G, Marzorati L, Marzola M, Miceli MD, Cantù M.G, Cavaletti G: Neurotoxicity of cisplatin +/- reduced glutathione in the first-line treatment of advanced ovarian cancer. Int J Gynecol Cancer 6:415-419, 1996 10. Bradley PP, Priebat DA, Christensen RD, Rothstein G: Measurement of cutaneous inflammation: Estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78:206-209, 1982 11. Brock PR, Bellman SC, Yeomans EC, Pinkerton CR, Pritchard J: Cisplatin ototoxicity in children: A practical grading system. Med Pediatr Oncol 19:295-300, 1991 12. Brock PR, Maibach R, Childs M, Rajput K, Roebuck D, Sul